A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells

International Journal of Cancer

Volumn 136, Issue 4, 2015, Pages E161-E172

  Fernando, Joan ^a   Malfettone, Andrea ^a   Cepeda, Edgar B ^a   Vilarrasa Blasi, Roser ^a   Bertran, Esther ^a   Raimondi, Giulia ^a   Fabra, Àngels ^a   Alvarez Barrientos, Alberto ^b   Fernández Salguero, Pedro ^b   Fernández Rodríguez, Conrado M ^c   Giannelli, Gianluigi ^d   Sancho, Patricia ^a   Fabregat, Isabel ^a,e  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b UNIVERSITY OF EXTREMADURA   (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY OF BARCELONA   (Spain)

Author keywords

CD44; EMT; Liver cancer; Sorafenib; TGF beta

Indexed keywords

CD133 ANTIGEN; CYTOKERATIN 18; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; SORAFENIB; STEM CELL FACTOR; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VIMENTIN; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; CD44 PROTEIN, HUMAN; NICOTINAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL VIABILITY; CONTROLLED STUDY; DRUG RESPONSE; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIOID CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; MESENCHYME CELL; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PHENOTYPE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; HEPG2 CELL LINE; HUMAN; LIVER NEOPLASMS, EXPERIMENTAL; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE, NUDE; NIACINAMIDE; PHENOTYPE; PHENYLUREA COMPOUNDS; TRANSFORMING GROWTH FACTOR BETA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84918815230     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29097     Document Type: Article

References (50)

1. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011; 140:1410-26
2. Tanaka S, Arii S. Molecular targeted therapies in hepatocellular carcinoma. Semin Oncol 2012;39: 486-92
3. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
4. Kudo M. Targeted therapy for liver cancer: updated review in 2012. Curr Cancer Drug Targets 2012;12:1062-72
5. Xie B, Wang DH, Spechler SJ. Sorafenib for treatment of hepatocellular carcinoma: A systematic review. Dig Dis Sci 2012;57:1122-29
6. Chow AK, Ng L, Lam CS, et al. The enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. PLoS One 2013;8:e78675
7. Thiery JP, Acloque H, Huang RY, et al. Epithelial- mesenchymal transitions in development and disease. Cell 2009;139:871-90
8. Nieto MA, Cano A. The epithelial-mesenchymal transition under control: global programs to regulate epithelial plasticity. Semin Cancer Biol 2012; 22:361-8
9. Gotzmann J, Huber H, Thallinger C, et al. Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-beta1 and Ha- Ras: steps towards invasiveness. J Cell Sci 2002; 115:1189-202
10. Valdes F, Alvarez AM, Locascio A, et al. The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor Beta in fetal rat hepatocytes. Mol Cancer Res 2002;1:68-78
11. Bertran E, Caja L, Navarro E, et al. Role of CXCR4/SDF-1 alpha in the migratory phenotype of hepatoma cells that have undergone epithelialmesenchymal transition in response to the transforming growth factor-beta. Cell Signal 2009;21: 1595-606
12. Reichl P, Haider C, Grubinger M, et al. TGF-beta in epithelial to mesenchymal transition and metastasis of liver carcinoma. Curr Pharm Des 2012;18:4135-47
13. Bertran E, Crosas-Molist E, Sancho P, et al. Overactivation of the TGF-beta pathway confers a mesenchymal-like phenotype and CXCR4- dependent migratory properties to liver tumor cells. Hepatology 2013;58:2032-44
14. Caja L, Bertran E, Campbell J, et al. The transforming growth factor-beta (TGF-beta) mediates acquisition of a mesenchymal stem cell-like phenotype in human liver cells. J Cell Physiol 2011; 226:1214-23
15. Katsuno Y, Lamouille S, Derynck R. TGF-beta signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol 2013;25: 76-84
16. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010;120:41-50
17. Oishi N, Wang XW. Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci 2011;7:517-35
18. Fernando J, Sancho P, Fernandez-Rodriguez CM, et al. Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. J Cell Physiol 2012;227:1319-25
19. Valdes F, Alvarez AM, Locascio A, et al. The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor Beta in fetal rat hepatocytes. Mol Cancer Res 2012;1:68-78
20. Caja L, Ortiz C, Bertran E, et al. Differential intracellular signalling induced by TGF-beta in rat adult hepatocytes and hepatoma cells: implications in liver carcinogenesis. Cell Signal 2006;19: 683-94
21. Carmona-Cuenca I, Roncero C, Sancho P, et al. Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its proapoptotic activity. J Hepatol 2008;49:965-76
22. Caja L, Sancho P, Bertran E, et al. Dissecting the effect of targeting the epidermal growth factor receptor on TGF-beta-induced-Apoptosis in human hepatocellular carcinoma cells. J Hepatol 2011;55:351-8
23. Tamada M, Nagano O, Tateyama S, et al. Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res 2012;72:1438-48
24. Mima K, Okabe H, Ishimoto T, et al. CD44s regulates the TGF-beta-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res 2012;72:3414-23
25. Johnsen HE, Kjeldsen MK, Urup T, et al. Cancer stem cells and the cellular hierarchy in haematological malignancies. Eur J Cancer 2009;45(Suppl 1):194-201
26. Ramdass B, Duggal R, Minev B, et al. Functional role of solid tumor stem cells in disease etiology and susceptibility to therapeutic interventions. J Stem Cells 2013;8:189-231
27. Rountree CB, Mishra L, Willenbring H. Stem cells in liver diseases and cancer: recent advances on the path to new therapies. Hepatology 2012; 55:298-306
28. Marquardt JU, Factor VM, Thorgeirsson SS. Epigenetic regulation of cancer stem cells in liver cancer: Current concepts and clinical implications. J Hepatol 2010;53:568-77
29. Marquardt JU, Raggi C, Andersen JB, et al. Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. Hepatology 2011;54:1031-42
30. Shi GM, Xu Y, Fan J, et al. Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol 2008;134:1155-63
31. Xin HW, Ambe CM, Hari DM, et al. Labelretaining liver cancer cells are relatively resistant to sorafenib. Gut 2013;62:1777-86
32. Liu LL, Fu D, Ma Y, et al. The power and the promise of liver cancer stem cell markers. Stem Cells Dev 2011;20:2023-30
33. Ponta H, Sherman L, Herrlich PA. CD44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33-45
34. Yang ZF, Ho DW, Ng MN, et al. Significance of CD901 cancer stem cells in human liver cancer. Cancer Cell 2008;13:153-66
35. Hagiwara S, Kudo M, Nagai T, et al. Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. Br J Cancer 2012;106:1997-2003
36. Mima K, Hayashi H, Imai K, et al. High CD44s expression is associated with the EMT expression profile and intrahepatic dissemination of hepatocellular carcinoma after local ablation therapy. J Hepatobiliary Pancreat Sci 2013;20:429-34
37. Fransvea E, Angelotti U, Antonaci S, et al. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 2008;47:1557-66
38. Mima K, Hayashi H, Kuroki H, et al. Epithelialmesenchymal transition expression profiles as a prognostic factor for disease-free survival in hepatocellular carcinoma: Clinical significance of transforming growth factor-beta signaling. Oncol Lett 2013;5:149-54
39. Franco DL, Mainez J, Vega S, et al. Snail1 suppresses TGF-beta-induced apoptosis and is sufficient to trigger EMT in hepatocytes. J Cell Sci 2010;123:3467-77
40. Chen X, Lingala S, Khoobyari S, et al. Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. J Hepatol 2011;55:838-45
41. van Zijl F, Mall S, Machat G, et al. A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression. Mol Cancer Ther 2011;10:850-60
42. Caja L, Kahata K, Moustakas A. Context-dependent action of transforming growth factor beta family members on normal and cancer stem cells. Curr Pharm Des 2012;18:4072-86
43. Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 2008;47: 2059-67
44. Xie Z, Choong PF, Poon LF, et al. Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion. Cancer Chemother Pharmacol 2008;62:949-57
45. Henry JC, Park JK, Jiang J, et al. miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2010;403:120-5
46. Ishimoto T, Nagano O, Yae T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011;19:387-400
47. Coriat R, Nicco C, Chereau C, et al. Sorafenibinduced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol Cancer Ther 2012;11:2284-93
48. Okabe H, Ishimoto T, Mima K, et al. CD44s signals the acquisition of the mesenchymal phenotype required for anchorage-independent cell survival in hepatocellular carcinoma. Br J Cancer 2014;110:958-66
49. Lee JS, Thorgeirsson SS. Comparative and integrative functional genomics of HCC. Oncogene 2006;25:3801-09
50. Lemmer ER, Friedman SL, Llovet JM. Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: The potential of gene expression profiling. Semin Liver Dis 2006;26:373-84.